37025-55-1 Usage
Uses
Used in Obstetric Applications:
(BUTYRYL1,TYR(ME)2)-1-CARBAOXYTOCIN TRIFLUOROACETATE SALT is used as an obstetric drug for controlling postpartum hemorrhaging. As an oxytocin receptor agonist, it stimulates the contraction of the uterus, effectively managing bleeding after childbirth. Its long-acting and rapid onset of action make it a valuable alternative to traditional oxytocin treatments.
Used in Lactation Stimulation:
(BUTYRYL1,TYR(ME)2)-1-CARBAOXYTOCIN TRIFLUOROACETATE SALT is also used to stimulate milk let-down due to its action on oxytocin receptors of myoepithelial cells. This application can be particularly beneficial for mothers who may experience difficulties in initiating or maintaining lactation.
Biochem/physiol Actions
Carbetocin is a potent agonist of the oxytocin receptor, with improved in vivo stability over oxytocin.
Check Digit Verification of cas no
The CAS Registry Mumber 37025-55-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,7,0,2 and 5 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 37025-55:
(7*3)+(6*7)+(5*0)+(4*2)+(3*5)+(2*5)+(1*5)=101
101 % 10 = 1
So 37025-55-1 is a valid CAS Registry Number.
InChI:InChI=1/C45H69N11O12S/c1-6-25(4)38-44(67)50-28(15-16-34(46)58)40(63)51-30(21-35(47)59)41(64)53-31(23-69-18-8-10-37(61)55(5)33(43(66)54-38)20-26-11-13-27(57)14-12-26)45(68)56-17-7-9-32(56)42(65)52-29(19-24(2)3)39(62)49-22-36(48)60/h11-14,24-25,28-33,38,57H,6-10,15-23H2,1-5H3,(H2,46,58)(H2,47,59)(H2,48,60)(H,49,62)(H,50,67)(H,51,63)(H,52,65)(H,53,64)(H,54,66)/t25-,28-,29-,30-,31-,32-,33-,38-/m0/s1
37025-55-1Relevant academic research and scientific papers
PROCESS FOR LARGE SCALE LIQUID PHASE SYNTHESIS OF CARBETOCIN AND ITS NOVEL INTERMEDIATES
-
Page/Page column 11; 25, (2017/11/06)
A process for large scale liquid phase synthesis of Carbetocin is disclosed. Novel intermediates of formula (A), formula (B), and processes for their preparation are also disclosed.
New, potent, and selective peptidic oxytocin receptor agonists
Wi?niewski, Kazimierz,Alagarsamy, Sudarkodi,Galyean, Robert,Tariga, Hiroe,Thompson, Dorain,Ly, Brian,Wi?niewska, Halina,Qi, Steve,Croston, Glenn,Laporte, Regent,Rivière, Pierre J.-M.,Schteingart, Claudio D.
supporting information, p. 5306 - 5317 (2014/07/08)
Mothers of preterm babies frequently have difficulty establishing or maintaining lactation, thought to be due to interference with the milk ejection reflex. Administration of exogenous oxytocin can produce alveolar contraction and adequate breast emptying resulting in establishment of successful lactation. The natural hormone oxytocin is not receptor-selective and may cause hyponatremia via V2 receptor mediated antidiuresis. We have designed a series of potent oxytocin analogues containing N-alkylglycines in position 7 with excellent selectivity versus the related V1a, V1b, and V2 vasopressin receptors and short half-life: agonists 31 ([2-ThiMeGly7]dOT), 47 (carba-6-[Phe2,BuGly 7]dOT), 55 (carba-6-[3-MeBzlGly7]dOT), and 57 (carba-1-[4-FBzlGly7]dOT) have EC50 values at hOTR 2000, IC50 at hV1aR > 500 nM, and total clearance in rats in the range of 60-80 mL min-1 kg-1. Compound 57 (FE 202767) is currently in clinical development for the treatment of preterm mothers requiring lactation support.
